Pliant Therapeutics Inc’s recent filing unveils that its President and CEO Coulie Bernard unloaded Company’s shares for reported $0.59 million on Jan 17 ’25. In the deal valued at $11.20 per share,52,419 shares were sold. As a result of this transaction, Coulie Bernard now holds 430,517 shares worth roughly $0.59 million.
Then, Cummings Keith Lamont sold 20,148 shares, generating $225,680 in total proceeds. Upon selling the shares at $11.20, the Chief Financial Officer now owns 262,608 shares.
Before that, Hull Hans sold 15,936 shares. Pliant Therapeutics Inc shares valued at $178,501 were divested by the Chief Business Officer at a price of $11.20 per share. As a result of the transaction, Hull Hans now holds 211,558 shares, worth roughly $0.29 million.
A number of analysts have revised their coverage, including Needham’s analysts, who decreased its forecast for the stock in early March from “a Buy” to “a Hold”. Stifel also remained covering PLRX and has decreased its forecast on March 03, 2025 with a “Hold” recommendation from previously “Buy” rating. Leerink Partners revised its rating on March 03, 2025. It rated PLRX as “a Market perform” which previously was an “an Outperform”.
Price Performance Review of PLRX
On Monday, Pliant Therapeutics Inc [NASDAQ:PLRX] saw its stock fall -1.45% to $1.36. Over the last five days, the stock has lost -15.00%. Pliant Therapeutics Inc shares have fallen nearly -89.67% since the year began. Nevertheless, the stocks have fallen -88.44% over the past one year. While a 52-week high of $16.10 was reached on 01/03/25, a 52-week low of $1.10 was recorded on 04/09/25.
Levels Of Support And Resistance For PLRX Stock
The 24-hour chart illustrates a support level at 1.3183, which if violated will result in even more drops to 1.2767. On the upside, there is a resistance level at 1.4133. A further resistance level may holdings at 1.4667.
